Dr. Luís Mendonça
Dr. Luís Mendonça


horário de atendimento

9H - 12H20

15H - 19H

09H - 12H

Nome Clínico: Dr. Luís Mendonça
Data de nascimento: 11/12/1981
Nº de inscrição na Ordem dos Médicos: 44898

Formação Académica:

Present, Hospital Assistant of the Ophthalmology Service at the Hospital de Braga.
Specialist in Medical and Surgical Retina: particular interest and experience in diagnosis and in medical/surgical retina treatment, vitreous and macular diseases, namely Age-Related Macular Degeneration (DMI), Diabetic Retinopathy, Retinal Vascular Occlusions.
Retinal Research Fellowship – Vitreous Retina Macula Consultants of New York - New York University (NYU) - New York, NY, USA.
2007 - 2010, Ophthalmology Specific Training (Specialized Internship) of the Ophthalmology Service at the Hospital de São João do Porto, Portugal.
2006, General Internship - Common Year at the Hospital de São João do Porto, Portugal.
1999 - 2005, Medicine Degree at the Faculdade de Medicina da Universidade do Porto.

Áreas preferenciais da atividade oftalmológica:

Medical and Surgical Retina.

Cargos / Títulos em Oftalmologia:

Retina LASER Treatment experience.
Cataract Curgery - Phacoemulsification - experience.
Vitreo-retinal Surgery experience.
Clinical Trials Researcher in the areas of ??Medical and Surgical Retina.
Author and Co-author of more than a dozen publications, in indexed national and international journals.
Clinical Participations as Researcher:
2008, VIEW 2 - investigator in Protocol VIEW 2 VEGF Trap Eye: investigation at efficacy and safety in wet AMD; Bayer Healthcare, Bayer Schering Pharma
Investigator in Protocol No. CRFB002A2402 SECURE: A phase IV, long term, open label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal neovascularization (CNV) secondary to age related macular degeneration (AMD). Novartis
Investigator in Protocol RETINA PROJECT 4: Contribution of the genetic component to the development of VRP - Replication and validation - multicentric study involving Donostia University Hospital (San Sebastián, Spain), Reina Sofía University Hospital (Córdoba, Spain), Vall d'Hebró Hospital (Barcelona, ??Spain), Instituto Barraquer (Barcelona, ??Spain), Vissum Institute of Ophthalmology (Alicante, Spain), IOBA (Valladolid, Spain), Hospital Universitario del Valladolid, Valladolid, Moorfields Eye Hospital (London, UK), Rotterdam Eye Hospital (Rotterdam, Netherlands), Hospital de São João (Porto, Portugal).